GILENYA

Serial Number 85124824
606

Registration Progress

Application Filed
Sep 8, 2010
Under Examination
Nov 8, 2011
Approved for Publication
Sep 13, 2011
Published for Opposition
Sep 13, 2011
Registered

Trademark Image

GILENYA

Basic Information

Serial Number
85124824
Filing Date
September 8, 2010
Published for Opposition
September 13, 2011
Abandonment Date
December 15, 2014
Drawing Code
3000

Status Summary

Current Status
Inactive
Status Code
606
Status Date
Dec 15, 2014
Classes
005

Rights Holder

Novartis AG

03
Address
CH-4002
Basel
CH

Ownership History

Novartis AG

Original Applicant
03
Basel CH

Novartis AG

Owner at Publication
03
Basel CH

Legal Representation

Attorney
Maury M Tepper, III

USPTO Deadlines

All Deadlines Cleared

All 8 deadline(s) have been cleared by subsequent events. No active deadlines at this time.

Application History

49 events
Date Code Type Description
Dec 15, 2014 ABN6 S ABANDONMENT - NO USE STATEMENT FILED
Dec 15, 2014 MAB6 O ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
May 1, 2014 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 30, 2014 EX5G S SOU EXTENSION 5 GRANTED
Apr 23, 2014 EEXT I SOU TEAS EXTENSION RECEIVED
Apr 23, 2014 EXT5 S SOU EXTENSION 5 FILED
Nov 5, 2013 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 4, 2013 EX4G S SOU EXTENSION 4 GRANTED
Oct 29, 2013 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 29, 2013 EXT4 S SOU EXTENSION 4 FILED
May 7, 2013 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 6, 2013 EX3G S SOU EXTENSION 3 GRANTED
May 4, 2013 EEXT I SOU TEAS EXTENSION RECEIVED
May 4, 2013 EXT3 S SOU EXTENSION 3 FILED
Nov 3, 2012 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 2, 2012 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL
Nov 2, 2012 EX2G S SOU EXTENSION 2 GRANTED
Oct 31, 2012 EEXT I SOU TEAS EXTENSION RECEIVED
Oct 31, 2012 EXT2 S SOU EXTENSION 2 FILED
May 5, 2012 EXRA E NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 3, 2012 EEXT I SOU TEAS EXTENSION RECEIVED
May 3, 2012 EXT1 S SOU EXTENSION 1 FILED
May 3, 2012 EX1G S SOU EXTENSION 1 GRANTED
Nov 8, 2011 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Sep 13, 2011 PUBO A PUBLISHED FOR OPPOSITION
Sep 13, 2011 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Aug 8, 2011 ALIE A ASSIGNED TO LIE
Aug 8, 2011 PREV O LAW OFFICE PUBLICATION REVIEW COMPLETED
Jul 27, 2011 CNEA R EXAMINERS AMENDMENT -WRITTEN
Jul 27, 2011 GNEA O EXAMINERS AMENDMENT E-MAILED
Jul 27, 2011 GNEN O NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Jul 27, 2011 XAEC I EXAMINER'S AMENDMENT ENTERED
Jul 27, 2011 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Jul 1, 2011 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 1, 2011 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 1, 2011 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Feb 16, 2011 CNRT R NON-FINAL ACTION WRITTEN
Feb 16, 2011 GNRT O NON-FINAL ACTION E-MAILED
Feb 16, 2011 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 25, 2011 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 25, 2011 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 25, 2011 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 17, 2010 DOCK D ASSIGNED TO EXAMINER
Dec 17, 2010 CNRT R NON-FINAL ACTION WRITTEN
Dec 17, 2010 GNRT F NON-FINAL ACTION E-MAILED
Dec 17, 2010 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 14, 2010 MDSC O NOTICE OF DESIGN SEARCH CODE MAILED
Sep 11, 2010 NWAP I NEW APPLICATION ENTERED
Sep 11, 2010 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Detailed Classifications

Class 005
Anti-infectives; Antibiotic preparations; Antifungal preparations; Antivirals; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the treatment and prevention of disorders of the nervous system, the immune system, the cardiovascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; Pharmaceutical preparations for the prevention and treatment of inflammatory disorders; Pharmaceutical preparations for the prevention and treatment of disorders or diseases in the fields of dermatology, ophthalmology, oncology, hematology and in tissue and organ transplantation, and for the treatment of gastroenterological disorders
First Use Anywhere: 0
First Use in Commerce: 0

Additional Information

Design Mark
The mark consists of two curved lines leading up to a stylized star to the left and above the word "GILENYA"; the color gray is intended to show shading or contrast only.
Color Claim
Color is not claimed as a feature of the mark.
Translation
The wording "GILENYA" has no meaning in a foreign language.

Classification

International Classes
005

USPTO Documents

Click to view cached USPTO documents for this trademark

Only administrators can request new documents from USPTO